GBT - Global Blood Therapeutics Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development61,21236,65716,324
Selling General and Administrative21,9159,7364,187
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-83,127-46,393-20,511
Income from Continuing Operations
Total Other Income/Expenses Net65933-296
Earnings Before Interest and Taxes-82,468-46,360-20,807
Interest Expense---
Income Before Tax-82,468-46,360-20,807
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-82,468-46,360-20,807
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-82,468-46,360-20,807
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-82,468-50,540-23,772